CDP 571 anti-tumor necrosis factor human antibody data

CTP (Slough, U.K.) announced Phase II data in 31 patients who have not responded to standard therapy, showing complete or near-complete remission from a single 5 mg/kg dose in 9 of 21 treated patients at two weeks.

One of the 10 patients who received placebo had a remission. ...